38 recruiting, 24 unknown, 10 completed, 7 active not recruiting. 54 Phase 1, 43 Phase 2, 12 Early Phase 1, 3 Not applicable, 3 Phase 3.
Follow B-cell Acute Lymphoblastic Leukemia: new trials by email Literature Review of B-cell Acute Lymphoblastic Leukemia trials Research Report on B-cell Acute Lymphoblastic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Of KITE-753 in R/R B-Cell ALL KITE-753 - B-cell Acute Lymphoblastic Leukemia | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 18 | 2026-12-31 | 2026-09-11 |
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | BeOne Medicines | 30 | 2026-12-01 | 2026-10-26 |
| A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia Blinatumomab Injection - B-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult | Phase 1 / Phase 2 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 26 | 2026-09-01 | 2026-08-11 |
| SNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia SNC116 - B-cell Acute Lymphoblastic Leukemia | Early Phase 1 | Not yet recruiting | Shanghai Simnova Biotechnology Co.,Ltd. | 28 | 2026-09-01 | 2026-09-21 |
| NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL Antigen-specific T cells CART/CTL and DCvac - B-Cell Acute Lymphoblastic Leukemia | Phase 1 | Terminated | Shenzhen Geno-Immune Medical Institute | 10 | 2026-06-01 | 2026-11-02 |
| A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) MK-1045, Blinatumomab, Acetaminophen - B-cell Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 340 | 2026-05-18 | 2026-10-30 |
| Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia Anti-CD19/CD22 Dual-Target Cord Blood CAR-T Cells, Fludarabine, Cyclophosphamide - B-cell Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Ruijin Hospital | 18 | 2026-05-13 | 2026-09-25 |
| Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy - B-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse | Phase 1 | Recruiting | Beijing GoBroad Hospital | 48 | 2026-03-15 | 2026-03-09 |
| Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia SYNCAR-100 Injection - B-Cell Acute Lymphoblastic Leukemia | Early Phase 1 | Recruiting | Zhejiang University | 16 | 2026-02-28 | 2026-02-24 |
| A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia Blinatumomab, Mini-CVD, MTX/ARA-C - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 3 | 2026-01-30 | 2026-08-18 |
| A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab B-Cell ALL, B-Cell Acute Lymphoblastic Leukaemia | Recruiting | Arkansas Children's Hospital Research Institute | 300 | 2026-01-13 | 2026-10-28 | |
| Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL CD22/CD19 Dual-Target CAR-T Cells - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Liping Dou | 20 | 2026-01-01 | 2026-06-15 |
| Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia CD22/CD19 Dual-Target CAR-T Cells - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Liping Dou | 30 | 2026-01-01 | 2026-06-25 |
| Study of GI001 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia GI001 - B-Cell Non-Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia | Early Phase 1 | Recruiting | Hematology department of the 920th hospital | 18 | 2025-11-28 | 2026-10-07 |
| A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia Fludarabine, Cyclophosphamide, CAR-T - B-cell Acute Lymphoblastic Leukemia | Phase 3 | Recruiting | Memorial Sloan Kettering Cancer Center | 130 | 2025-10-20 | 2026-10-05 |
| A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia Chimeric Antigen Receptor T Cells (CAR-T) - B-cell Acute Lymphoblastic Leukemia | Phase 1 | Not yet recruiting | Shanghai Tongji Hospital, Tongji University School of Medicine | 36 | 2025-07-10 | 2025-06-29 |
| A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL) HY004, Cyclophosphamide, Fludarabine Phosphate - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Withdrawn | Juventas Cell Therapy Ltd. | 2025-06-30 | 2025-08-08 | |
| Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101 - B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Vironexis Biotherapeutics Inc. | 32 | 2025-05-30 | 2026-10-26 |
| Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone - B-cell Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Children's Hospital Medical Center, Cincinnati | 28 | 2025-05-21 | 2026-02-18 |
| Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies DuoCAR20.19.22-D95, Fludarabine (Conditional therapy), Cyclophosphamide (Conditional therapy) - B-Cell Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | University of Kansas Medical Center | 54 | 2025-03-31 | 2026-05-14 |
Showing 20 of 97. Sign in to see all of them.
Burkitt Lymphoma (97) · Lymphoma, B-Cell (15) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (14) · Recurrence (11) · Lymphoma, Large B-Cell, Diffuse (7) · Leukemia (6) · Lymphoma (5) · Lymphoma, Non-Hodgkin (5) · Leukemia, B-Cell (4) · Leukemia, Myeloid, Acute (4) · Lymphoma, Mantle-Cell (4) · Neoplasm, Residual (4) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Hematologic Diseases (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2)
DNA Virus Infections (97) · Epstein-Barr Virus Infections (97) · Hemic and Lymphatic Diseases (97) · Herpesviridae Infections (97) · Immune System Diseases (97) · Immunoproliferative Disorders (97) · Infections (97) · Neoplasms by Histologic Type (97) · Tumor Virus Infections (97) · Virus Diseases (97) · Lymphatic Diseases (96) · Lymphoproliferative Disorders (96) · Neoplasms (95) · Lymphoma (92) · Lymphoma, Non-Hodgkin (92)
blinatumomab (12) · Cyclophosphamide (10) · fludarabine (9) · tisagenlecleucel (7) · Dexamethasone (5) · Immunotherapy, Adoptive (4) · Inotuzumab Ozogamicin (4) · tocilizumab (3) · venetoclax (3) · Cytarabine (2) · Etoposide (2) · Injections (2) · Prednisone (2) · Vincristine (2) · fludarabine phosphate (2)
The First Affiliated Hospital of Soochow University (6) · Novartis Pharmaceuticals (5) · Beijing GoBroad Hospital (3) · Hebei Yanda Ludaopei Hospital (3) · Juventas Cell Therapy Ltd. (3) · Memorial Sloan Kettering Cancer Center (3) · Zhejiang University (3) · Anhui Provincial Hospital (2) · Liping Dou (2) · M.D. Anderson Cancer Center (2) · Merck Sharp & Dohme LLC (2) · University of Colorado, Denver (2) · Yan'an Affiliated Hospital of Kunming Medical University (2) · 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (1) · Abramson Cancer Center at Penn Medicine (1)
China (45) · United States (31) · France (7) · Canada (6) · Italy (6) · United Kingdom (6) · Netherlands (5) · Spain (5) · Australia (4) · Belgium (4) · Germany (4) · Japan (4) · Denmark (3) · Israel (3) · Sweden (3)
Kevin Curran, MD (2) · Abdel-Azim Hisham, MD (1) · Aibin Liang MD,Ph.D. (1) · Aibin Liang, Dr. (1) · Aloysius Ho, MD (1) · Christian Schmidt, MD (1) · Dario Campana (1) · David Shook, MD (1) · Dorothy Sipkins, MD (1) · Elias Jabbour, MD (1) · Franco Locatelli, MD, PhD (1) · He Huang, MD (1) · He Huang, PhD (1)
PMID 41671463, PMID 33496754, PMID 34353848, PMID 34432863, PMID 35422096, PMID 26684414, PMID 27209293, PMID 28054442, PMID 29358182, PMID 29385370, PMID 30254079, PMID 31606419, PMID 32589970, PMID 32619115, PMID 33308471, PMID 33843815, PMID 34893603, PMID 36228643, PMID 36399695, PMID 36821767, PMID 37647601, PMID 38135369, PMID 40367950, PMID 41110448, PMID 41199560, PMID 42525896, PMID 42789493
2016 (2), 2017 (2), 2023 (2), 2015 (1), 2025 (1)